Metastasis Steps — Explain metastasis steps conceptually (EMT, invasion, intravasation, colonization) (intro)

For most of medical history, cancer was understood as a localized disease—a malignant mass that could be surgically excised if caught early. The realization that tumors could spread to distant sites transformed oncology from a largely surgical discipline into a field requiring systemic approaches. Metastasis, the process by which cancer cells disseminate from a primary tumor to form secondary colonies in remote tissues, accounts for approximately 90 % of cancer-related mortality. Understanding the molecular steps that drive metastasis has therefore become one of the most consequential goals in biomedical research, shaping everything from chemotherapy regimens to the development of targeted immunotherapies.

The central question driving modern metastasis research is deceptively simple: How does a stationary epithelial cell acquire the ability to migrate, survive in circulation, and re-establish proliferative growth in a foreign tissue? Answering this question requires an understanding of a sequential, multi-step cascade—each step presenting a distinct biological barrier that the cell must overcome.

Metastasis is not a single event but a metastatic cascade—an ordered series of biological steps, each of which must be completed for a cancer cell to successfully seed a secondary tumor. These steps can be organized into four major phases: epithelial-mesenchymal transition (EMT), local invasion, intravasation and survival in circulation, and extravasation and colonization. A failure at any single step aborts metastasis entirely, which explains why the process is remarkably inefficient—fewer than 0.01 % of cells that enter the bloodstream successfully form a macrometastasis.

The diagram above presents the metastatic cascade as a linear sequence, but it is important to appreciate that these steps are interconnected through feedback loops and microenvironmental signals. For instance, signals from distant organs can precondition a pre-metastatic niche even before the first cancer cell arrives, secreting exosomes and cytokines that prime the soil for future colonization. Similarly, the degree of EMT may be partial rather than complete—cells can exist in hybrid epithelial/mesenchymal states that offer both motility and the ability to form cell clusters, which paradoxically survive circulation better than single cells. These nuances underscore the importance of viewing metastasis as a dynamic, adaptable process rather than a fixed pipeline.

Step 1 — Epithelial-Mesenchymal Transition (EMT)

In normal epithelia, cells are tightly connected by adherens junctions, tight junctions, and desmosomes, with E-cadherin serving as the central adhesion molecule. During EMT, transcription factors such as SNAIL, SLUG, TWIST, and ZEB1/2 are upregulated by signals from TGF-β, Wnt, Notch, and receptor tyrosine kinase pathways. These transcription factors directly repress the CDH1 gene (encoding E-cadherin) and activate genes for mesenchymal proteins including N-cadherin, vimentin, and fibronectin. The net result is a cell that detaches from its neighbors, reorganizes its actin cytoskeleton into stress fibers, becomes motile, and acquires resistance to apoptosis—a phenotype fundamentally suited for invasion.

Step 2 — Local Invasion

Once freed from epithelial constraints, the cancer cell must penetrate the basement membrane—a dense sheet of type IV collagen, laminin, and proteoglycans—and migrate through the stromal extracellular matrix (ECM). This is accomplished through secretion of matrix metalloproteinases (MMPs)—zinc-dependent endopeptidases that cleave collagen, elastin, and other ECM components. MMP-2 and MMP-9, which degrade type IV collagen, are particularly important. Cancer cells also extend actin-rich protrusions called invadopodia that concentrate protease activity at the leading edge, physically drilling through tissue barriers. Chemotactic gradients of EGF, CXCL12, and other factors guide directional migration toward blood vessels.

Step 3 — Intravasation & Survival in Circulation

To enter the bloodstream or lymphatic system, cancer cells must cross the endothelial barrier. Tumor-associated macrophages often assist this process, forming paracrine signaling loops with cancer cells near blood vessels—a phenomenon termed TMEM (tumor microenvironment of metastasis) doorways. Once in circulation, cells face extreme shear forces (blood flow can reach 1–10 dyn/cm²), anoikis (apoptosis triggered by loss of ECM attachment), and immune attack by natural killer (NK) cells and macrophages. Circulating tumor cells (CTCs) counteract these threats by coating themselves with platelets, which shield them from immune recognition and shear stress, and by traveling in clusters that have up to 50-fold greater metastatic potential than single cells.

Step 4 — Extravasation & Colonization

CTCs arrest at distant capillary beds, where the narrow vessel diameter physically traps them. Adhesion molecules such as selectins and integrins mediate attachment to the endothelium. The cells then transmigrate across the vessel wall into the parenchyma of the target organ—a process that mirrors leukocyte extravasation during inflammation. Once in the new tissue, the cancer cell faces the greatest bottleneck: colonization. The foreign microenvironment often lacks the growth factors, ECM composition, and stromal support the cell evolved in. Many cells enter a state of dormancy, remaining quiescent for months to decades. Those that eventually reactivate may undergo mesenchymal-epithelial transition (MET)—the reverse of EMT—recovering proliferative capacity and forming a clinically detectable macrometastasis.

Partial EMT and the Hybrid State

A major revision of the original EMT model is the recognition that tumor cells frequently exist in hybrid epithelial/mesenchymal (E/M) states rather than fully converting from one phenotype to the other. Cells in a hybrid state retain some epithelial features—such as partial cell–cell adhesion—while simultaneously expressing mesenchymal markers that confer motility. This allows them to migrate collectively as clusters rather than as isolated cells. CTC clusters have been shown to have a 23- to 50-fold higher metastatic potential than individual CTCs, likely because they resist anoikis, evade immune detection more effectively, and carry stromal cells that provide survival signals.

Organ Tropism — Why Certain Cancers Metastasize to Specific Sites

Paget's seed-and-soil hypothesis has been validated at the molecular level. The concept of the pre-metastatic niche explains organ tropism: primary tumors secrete exosomes containing specific integrins that "address" them to particular organs. For example, exosomal integrin α6β4 targets the lungs, while integrin αvβ5 targets the liver. These exosomes reprogram resident stromal cells, recruit bone marrow-derived cells, and remodel the ECM, creating a hospitable microenvironment before cancer cells arrive.

Consider a ductal carcinoma cell in the breast. Using the metastatic cascade framework, trace the molecular events that would enable this cell to form a bone metastasis.

Because metastasis is a multi-step process, each step presents a potential therapeutic intervention point. However, the clinical reality is that most anti-metastatic strategies remain in preclinical or early clinical development, in part because metastasis is often already underway by the time a primary tumor is diagnosed. The table below outlines the current landscape of strategies targeting each cascade step, along with their strengths and limitations.

The introductory model of the metastatic cascade presented in this lesson provides a solid conceptual foundation, but advanced research has revealed additional layers of complexity. The table below highlights how several concepts introduced here connect to active areas of investigation that you will encounter in upper-division oncology and molecular biology courses.

Perhaps the most exciting frontier is the integration of single-cell transcriptomics and spatial transcriptomics with metastasis research. These technologies allow researchers to map the gene expression profiles of individual cells within a tumor, identifying the rare subpopulations that are primed for metastasis. Combined with lineage-tracing experiments in mouse models, these approaches are revealing that metastatic competence may be established much earlier in tumor evolution than previously appreciated—possibly at the stage of a pre-malignant lesion.